New drug shows promise for Hard-to-Treat hodgkin lymphoma
NCT ID NCT04318080
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study tested a drug called tislelizumab in 46 people whose Hodgkin lymphoma had come back or didn't respond to prior treatments. The goal was to see if the drug could shrink or eliminate tumors. Participants received the drug until their disease worsened or side effects became too severe. The study found that some patients experienced significant tumor reduction, offering a potential new option for this difficult-to-treat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-2013, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112-5550, United States
-
Monash Health
Clayton, Victoria, VIC 3168, Australia
-
University of Tennessee Medical Center
Knoxville, Tennessee, 37920-1511, United States
Conditions
Explore the condition pages connected to this study.